Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial by Vosough-Ghanbari, Sanaz et al.
Advance Access Publication 27 February 2008 eCAM 2010;7(4)465–470
doi:10.1093/ecam/nen018
Original Article
Effects of Satureja khuzestanica on Serum Glucose, Lipids
and Markers of Oxidative Stress in Patients with Type 2
Diabetes Mellitus: A Double-Blind Randomized Controlled Trial
Sanaz Vosough-Ghanbari
1, Roja Rahimi
1, Shabnam Kharabaf
1, Shima Zeinali
1,
Azadeh Mohammadirad
1, Somayeh Amini
2, Nargues Yasa
3, Alinazar Salehnia
1,
Tayebeh Toliat
1, Shekoufeh Nikfar
4, Bagher Larijani
2 and Mohammad Abdollahi
1
1Faculty of Pharmacy and Pharmaceutical Sciences Research Center (PSRC),
2Endocrinology and Metabolism
Research Center (EMRC) and Faculty of Medicine,
3Medicinal Plants Research Center (MPRC), Tehran University
of Medical Sciences (TUMS) and
4Drug Selecting Committee, Food and Drug Organization, and Food and Drug
Laboratory Research Center, Tehran, Iran
Satureja khuzestanica is an endemic plant of Iran that is widely distributed in the Southern part
of the country. It has antioxidant properties and thus it seems to be useful in diseases related to
oxidative stress such as diabetes and hyperlipidemia. The present study investigates the effect of
S. khuzestanica supplement in metabolic parameters of hyperlipidemic patients with type 2
diabetes mellitus. Twenty-one hyperlipidemic patients with type 2 diabetes mellitus were
randomized in a double blind, placebo controlled clinical trial to receive either S. khuzestanica
(tablets contain 250mg dried leaves) or placebo once a day for 60 days. Blood samples were
obtained at baseline and at the end of the study. Samples were analyzed for levels of glucose,
total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, creatinine, thiobarbituric acid
reactive substances (TBARS) as marker of lipid peroxidation and ferric reducing ability (total
antioxidant power, TAP). Treatment of patients by S. khuzestanica for 60 days induced
significant decrease in total cholesterol (P=0.008) and LDL-cholesterol (P=0.03) while
increased HDL-cholesterol (P=0.02) and TAP (P=0.007) in comparison with the baseline
values. S. khuzestanica did not alter blood glucose, triglyceride, creatinin and TBARS levels. In
comparison with baseline values, no significant change was observed in blood glucose, total
cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, creatinine, TBARS and TAP in
placebo-treated group. Usage of S. khuzestanica as a supplement to drug regimen of diabetic
type 2 patients with hyperlipidemia is recommended.
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Introduction
Satureja khuzestanica Jamzad (Marzeh khuzestani in
Persian, family of Lamiaceae, sub family of Nepetoidae)
is an endemic plant that is widely distributed in the
Southern parts of Iran. It is a subshrub, branched stem
30cm high, densely leafy, broadly ovaiate-orbicular
covered with white hairs (1). Base of the leaves is
attenuate and petioliform. It is famous for its thera-
peutic value as an analgesic and antiseptic in folk
medicine (2).
In the recent years, antimicrobial (3–5), antiviral (6,7),
antioxidant (8–10), antiproliferative (11), antiprotozoal
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properly cited.(12,13), antifungal (14,15), anti-inflammatory and anti-
nociceptive (16,17), antidiarrheal (18) and vasodilatory
(19,20) activities were reported from different species of
Satureja.
It has been shown that hydroethanolic extract of
S. khuzestanica has anti-inflammatory and antinocicep-
tive properties in carrageenan-induced rat paw edema
and formalin test comparable with those of indomethacin
and morphine (21). The methanolic extract of the aerial
parts of S. khuzestanica has been investigated for
its antimicrobial activity. The maximum antibacterial
and antifungal activities has been observed against
Staphylococcus aureus and Candida albicans (22).
Significant decrease in fasting blood glucose and
triglyceride levels were observed with essential oil of
S. khuzestanica in diabetic and hyperlipidemic rats.
A significant decrease in the normal lipid peroxidation
and an increase in body antioxidant power were reported
while the cholesterol level did not change significantly in
hyperlipidemic rats (23). It has been reported that
essential oil from S. khuzestanica does not affect blood
glucose concentrations but decreases hepatic phosphoe-
nolpyruvate carboxy kinase activity and increases
hepatic glycogen phosphorylase in rats (24). Study on
the effect of oral administration of essential oil from
S. khuzestanica in male rat fertility has revealed
significant improvement in all parameters of libido such
as potency, fecundity, fertility index and litter size.
Moreover, concentrations of FSH and testosterone and
the weights of testes, seminal vesicles and ventral prostate
weights were significantly increased. Histopathological
analysis showed that the number of spermatogonium,
spermatid cords, Leydig cells and spermatozoids was
increased and Sertoli cells were hypertrophic (25).
Essential oil from S. khuzestanica has protected mice
from experimentally induced inflammatory bowel disease
and significantly decreased lipid peroxidation in bowel
of animals (26). Primary acute toxicity and teratogeni-
city tests were also performed and confirmed plant’s
safety (23).
One of the specific identifying characteristics of the
subfamily Nepetoidae is that its representatives contain
<0.5% essential oil (27). The main component of
essential oil of S. khuzestanica is carvacrol (28). Other
constituents identified in this plant are flavones, triterpe-
noids, steroids and tannins (29). Both carvacrol and
flavonoids have been found to have antioxidant proper-
ties (30–33). Lipid peroxidation and consequent oxidative
stress are increased in diabetes and hyperlipidemia, and
have been proposed to play roles in the pathogenesis of
these diseases (34–37). The above-mentioned studies in
animals confirmed the safety of S. khuzestanica. In the
present study, the antidiabetic, antihyperlipidemic and
antioxidant effects of S. khuzestanica were investigated in
patients with type 2 diabetes mellitus.
Methods
Plant Collection and Tablet Preparation
The aerial parts of the S. khuzestanica were collected
during the flowering stage in June 2000 from
Khorramabad in the Lorestan province of Iran. The
plant was identified by the Department of Botany of the
Research Institute of Forests and Rangelands (TARI)
in Tehran. A voucher specimen (No. 58416) has been
deposited at the TARI Herbarium. The plant was culti-
vated in Khorramabad and the aerial parts of the plant
were collected during the flowering stage. The aerial parts
were air dried at ambient temperature in the shade.
Tablets were prepared from dried leaves of plant (each
tablet contained 250mg of dried leaves). Other ingredi-
ents of tablet were lactose, microcrystalline cellulose,
starch, poly vinyl pyrollidone (PVP) and magnesium
estearate. These ingredients were pressed with hardness of
5–7kg and the final mean weight of tablet was 375mg.
The pressed tablets were film coated with hydroxy propyl
methyl cellulose, poly ethylene glycol 4000, talc, titanium
dioxide, PVP, distilled water and ethanol.
Patient Selection
In this randomized, prospective, double-blind controlled
clinical trial, the database contains details of patients’
age, sex, clinical history, previous pharmacologic thera-
pies, hospitalizations and specialist consultations. We
recruited 21 (12 male and 9 female) patients with type 2
diabetes mellitus with a mean age of 50.65 from out-
patient clinic of a University Hospital. Diabetic patients
were chosen according to American Diabetes Association
(ADA) criteria (38). The patients were controlled by diet
and oral antidiabetic drugs. Diabetics with hyperlipide-
mia who met the criteria for pharmacologic treatment
according to National Cholesterol Education Program
(NCEP) Adult Treatment Panel III (ATP III) guideline
for diabetic patients were recruited (39). All patients were
receiving antidiabetic and antihyperlipidemic medications
at least 3 months before beginning the experiment.
Exclusion criteria were the followings: uncontrolled
hypertension (systolic blood pressure >140mm Hg and/
or diastolic blood pressure >90mm Hg); uncontrolled
hypothyroidism; obstructive hepatic or biliary disease;
alcoholism, smoking; autoimmune disease; chronic pan-
creatitis; active liver disease or hepatic dysfunction
[i.e. alanine aminotransferase (ALT), aspartate amino-
transferase (AST) and total bilirubin higher than 2-fold
the upper limit of normal]; nephritic syndrome or renal
dysfunction (i.e. serum creatinine concentration
>1.5mgdl
1); concomitant participation in other clinical
studies; use of heparin and/or oral anticoagulants;
pulmonary infections; gangrene; diabetic foot ulceration;
treatment with insulin and/or use of multivitamins and
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treated with steroids (unless administered topically or for
post-menopausal hormone replacement therapy), cyclos-
porine A, erythromycin, or ketoconazole were also
excluded; as well as patients with a history of myocardial
infarction, angioplasty, or major surgery in the 6 months
before the beginning of the study. Pregnant, possibly
pregnant, or breastfeeding women were excluded from
the study. Women of childbearing age were required to
use an effective method of birth control throughout the
study.
The subjects were completely informed of the purpose,
procedure and hazards of the trial and were free to leave
the trial at any time. All patients signed informed written
consent before being included in the study. The research
followed guidelines of the Declaration of Helsinki and
Tokyo for humans, and was approved by Ethics
Committee on Human Experimentation of PSRC/TUMS.
Patients who met the eligibility criteria were randomly
assigned to one of the two treatment groups according
to a simple randomization scheme. Group I (n=11)
received S. khuzestanica tablets (250mg) once a day for
60 days and group II (n=10) received placebo with the
same regimen. The subjects were asked not to alter their
usual diets and physical activity throughout the study
and any changes in their medication were avoided
whenever possible.
Sample Collection and Handling
After 12–14h overnight fasting, between 08:00 and
10:30h and before taking any oral hypoglycemic
agent(s), 10ml blood sample was collected from each
subject in tubes containing heparin, before beginning
of experiment and after 60 days administration of
S. khuzestanica or placebo. After centrifugation of
blood at 3000g for 30min at 4C, the plasma super-
natant fluid was separated and stored at 80C until
analyzed further.
Body mass index, blood pressure, serum total choles-
terol (TC), low-density lipoprotein-cholesterol (LDL-C),
high-density lipoprotein-cholesterol (HDL-C), triglyceride
(TG), fasting blood glucose and serum creatinine were
measured at the start and after 60 days of treatment.
Total Antioxidant Power (TAP) Assay
Antioxidant power of plasma was determined by
measuring their ability to reduce Fe
3+ to Fe
2+ estab-
lished as named (ferric reducing ability of plasma, FRAP)
test that described previously (40). Briefly, in this test, the
medium is exposed to Fe
3+ and the antioxidants present
in medium start to produce Fe
2+ as an antioxidant
activity. The FRAP reagent prepared freshly, contained
25ml of 300mM acetate buffer (pH 3.6) plus 2.5ml of
10mM 2,4,6-tripyridyl-s-triazine (TPTZ) solution in
40mM HCl and 2.5ml of 20mM ferric chloride
(FeCl3-6H2O). The complex between Fe
2+ and TPTZ
gives a blue color with absorbance at 593nm.
Lipid Peroxidation Assay
The method based on the reaction of malonedialdehyde
(MDA) as the end product of the oxidation of
polyunsaturated fatty acids and its concentration in the
medium is an established measure of lipid peroxidation
extent. In this test the reaction of MDA with TBA
creates a complex which is determined spectrophotome-
trically while lipid peroxidation in samples are assessed
in terms of thiobarbituric acid (TBA) thiobarbituric
acid reactive substances (TBARS) produced. Briefly, the
samples were diluted by buffered saline (1:5) and 800ml
of trichloroacetic acid (TCA, 28% w/v) was added to
400ml of this mixture and centrifuged in 3000g for
30min. Then, the precipitation was dissolved in sulfuric
acid and 600ml of the mixture was added to 150mlo f
TBA (1% w/v). The mixture was then incubated for
15min in a boiling water bath. Following incubation,
4ml of n-butanol was added, the solution was centri-
fuged, cooled and the absorption of the supernatant was
recorded at 532nm using a UV-160-A Shimadzu double
beam spectrophotometer (Japan). The calibration curve
of a 1,1,3,3-tetraethoxypropan standard solution was
used to determine the concentrations of TBA-MDA
adducts in samples (41).
Statistical Analysis
The statistical analysis was performed with the use of
StatsDirect version 2.6.2. Continuous data are expressed
as meanSE. Statistical analysis was initially performed
by Kolmogorov-Smirnov normality test. Unpaired two-
sample student’s t-test was used for analysis of contin-
uous data and Chi-square test was used for categorical
data if applicable. A P-value <0.05 was considered to be
statistically significant.
Results
Patients’ Characteristics
Twenty-one patients with type 2 diabetes mellitus
(12 male and 9 female) who fulfilled the enrolment
criteria entered into the study between July 2006 and
January 2007. Eleven patients were randomized to receive
S. khuzestanica and 10 to receive placebo. No patients
were withdrawn from the study. Demographic character-
istics did not differ significantly between two groups
(Table 1). No adverse events were reported from the
subjects throughout the study period.
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Oxidative Stress Biomarkers
Table 2 shows changes found on metabolic parameter
values in both groups between baseline and end of
therapy. Patients in the S. khuzestanica group showed
significant decrease in total cholesterol (P=0.008), LDL-
C( P=0.03) and increase in HDL-C (P=0.02) and TAP
(P=0.007) measured from baseline to 2 months while
patients in the placebo group showed no changes. The
other parameters including blood glucose, triglyceride,
creatinin and TBARS were not significantly altered in
S. khuzestanica group.
Discussion
Recently, there has been a considerable interest in finding
natural antioxidants from plant materials to replace
synthetic ones. Data from both scientific reports and
laboratory studies show that plants contain a large
variety of substances that possess antioxidant activity
(42). Phytochemicals with antioxidant effects include
some cinnamic acids, coumarins, diterpenes, flavonoids,
lignans, monoterpenes, phenylpropanoids, tannins and
triterpenes (43). Therefore, it seems that plants particu-
larly those with high levels and strong antioxidant
compounds have an important role in improvement of
disorders involving oxidative stress such as diabetes
mellitus (37). S. khuzestanica, an endemic plant of Iran,
possess antioxidant properties (23,26) and is expected to
be useful in diabetes and its complications.
The results of this study, show the significant effects of
S. khuzestanica in improving patients’ total cholesterol,
LDL-C, HDL-C and TAP. In previous study, it was
revealed that S. khuzestanica significantly decrease fasting
blood glucose and triglyceride levels in diabetic and
hyperlipidemic rats. It also improved the lipid peroxida-
tion and TAP levels (23). In another investigation, it was
reported that S. khuzestanica does not affect blood
glucose concentrations of rats (24). The main constituents
of S. khuzestanica are isopropanoids such as carvacrol,
thymol and flavonoids. It has been shown that thymol
and carvacrol significantly decrease the serum cholesterol
levels. They increased microsomal geranyl pyrophosphate
pyrophosphatase activity by 2-fold. The structural
diversity of the isopropanoids which suppress cholesterol
synthesis may be reconciled by their ability to increase
pyrophosphatase activity, thus leading to the production
of the endogenous, post-transcriptional regulator of
3-hydroxy-3-methylglutaryl coenzyme A reductase activ-
ity (44). Flavonoids have also shown antioxidant and
anti hyperlipidemic properties. Soy isoflavones sig-
nificantly reduced serum total and LDL-C but did
not change HDL-C and triacylglyceride (45). Covas
et al. (46) reported that consumption of polyphenol-
rich olive oil increases HDL-C levels and lowers levels
of oxidative stress markers and oxidized LDL-C.
Table 2. Levels of blood glucose, triglyceride, total cholesterol, LDL-C, HDL-C, creatinine, TAP, and lipid peroxidation before and after
administration of Satureja Khuzestanica or placebo
Satureja khuzestanica (n=11) Placebo (n=10)
Parameters Before After P-value Before After P-value
Glucose (mgdl
1) 16310.4 1608.9 0.7 165.917 20112 0.37
Triglyceride (mgdl
1) 147.222.7 16737 0.22 15517.1 230.915.1 0.12
Total cholesterol (mgdl
1) 202.83.5 156.24.2 0.008 189.16.5 2149 0.1
LDL-C (mgdl
1) 1204.5 1033.9 0.03 1236 1226.6 0.8
HDL-C (mgdl
1) 45.33.2 501.6 0.02 452 44.43.2 0.3
Creatinine (mgdl
1) 1.020.04 1.070.05 0.42 1.240.1 1.242.2 1
TAP (mmoll
1) 33648 47724 0.007 3810.45 41715.8 0.1
TBARS (mmoll
1) 15217.3 16419.1 0.51 15112.5 16419.1 0.1
HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TAP, total antioxidant power; TBARS, thiobarbituric acid
reactive substances.
The values are expressed as meanSE.
Table 1. Baseline characteristics of subjects
Satureja khuzestanica
(n=11)
Placebo
(n=10)
Age (year) 50.652.11 51.712.05
Male/female (n) 6/5 6/4
SBP (mmHg) 128.603.67 127.583.71
DBP (mmHg) 80.703.03 81.083.60
BMI (kgm
2) 26.351.70 27.632.44
HbA1c (%) 7.251.42 7.651.50
Concomitant therapy
Glibenclamide (n)8 6
Metformin (n)5 5
Statins (n)9 9
fibrates (n)2 1
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body
mass index; HbA1c, glycated hemoglobin; n, number of patients.
The values are expressed as meanSE.
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malathion-induced toxicity through improvement of
oxidative stress parameters (47). Since free radicals has
a pivotal role in pathogenesis and complications of
diabetes (37), every natural or synthetic compound that
can reduce oxidative stress may be beneficial in the
management of diabetes (48–53). One of our expectations
in the present study was to observe significant reductions
in blood glucose and level of lipid peroxidation by
S. khuzestanica treatment but this did not happen. The
first thing that comes to our mind is that dose of
S. khuzestanica was low and duration of the study was
small. On the other hand, disturbed lipid profile is
usually observed in diabetic patients and most of
diabetics usually receive lipid lowering agents mostly
statins that accompany with some adverse effects and
also costs a lot for diabetic patients (54,55). Introduction
of new herbal medicines like S. khuzestanica as a drug
with low price and safe can be helpful.
Conclusion
In summary, it seems that S. khuzestanica have a lipid
lowering and antioxidant properties in human and since
it has not shown any adverse effects, it could be used as a
supplement in diabetic patients with hyperlipidemia. The
exact role of this herbal supplement in management of
hyperlipidemic type-2 diabetic patients remains to be
elucidated by larger sample size and longer term clinical
trials.
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